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PH-SENSITIVE MUCOADHESIVE
FILM-FORMING GELS AND WAX-FILM
COMPOSITES SUITABLE FOR TOPICAL
AND MUCOSAL DELIVERY OF MOLECULES

water-soluble, bioerodable device for the delivery of drugs,
and speci?cally dyclonine, to mucosal surfaces. The device

FIELD OF THE INVENTION

Both the adhesive layer and the nonadhesive layer consist of
water-soluble polymers such as cellulose-based polymers.
The Tapolsky patent does not teach the use of ?lm-forming

US. Pat. No. 5,800,832 by Tapolsky et al. relates to a

comprises an adhesive layer as well as a non-adhesive layer.

gels comprised of pH-sensitive polymers and water-insoluble

The present invention relates to compositions and methods

mucoadhesive polymers that form ?lms due to changes in pH
and/or desolvation of the polymers. Further, the Tapolsky

to treat the skin and mucosal surfaces with mucoadhesive

?lm-forming gels and wax-?lm composites that are pH-sen
sitive. The invention also relates to using such pH-sensitive
?lm-forming gels and wax-?lm composites to deliver mol
ecules of interest, namely active pharmaceuticals. The inven

patent does not teach the use of pH-sensitive wax-?lm com
posites intended to remain adhered to the skin or mucosal

surface for a prolonged period of time.
US. Pat. No. 5,955,097 by Tapolsky et al. relates to a non
water-soluble gel, which adheres to mucosal surfaces and
body tissues upon application and forms a ?lm. The gel com
prises at least one water-insoluble cellulose-based polymer, a
non-aqueous solvent, and at least one active pharmaceutical.
The patent teaches that upon application to the mucosal sur

tion also relates to the use of said pH-sensitive ?lm-forming

gels and wax-?lm composites to deliver molecules of interest,
such as small molecules, peptides, proteins, and nucleic acids
either locally to act at the site of administration or for the

absorption of said molecules of interest across biological
membranes into the systemic circulation.
20

BACKGROUND OF THE INVENTION

Pharmaceutical formulations intended to deliver drugs
topically, either for local action at the site of administration or

for absorption into the systemic circulation, have been

into ?lms. The Tapolsky patent further teaches the use of 50 to

80% ethanol by weight in the pharmaceutical gel. The Tapol
25

sprays, or ?lms. In either case, one speci?c requirement is that
the dosage form remains at the administration site for a suf
?cient amount of time so that the drug may function as

needed. A second speci?c requirement is that the dosage form
must consist of pharmaceutically acceptable materials. Many
of the reported and commercially available delivery systems
intended for topical and mucosal delivery are aqueous-based

formulations comprising water-soluble excipients. However,

polymers that form ?lms due to changes in pH and/ or desol
30

attempt to prolong the residence time at the application site,
researchers have described the use of water-insoluble excipi
ents in the formulations. However, most often the use of
water-insoluble excipients necessitates the use of non-aque
ous solvents to dissolve the excipients. Excessive and
repeated administration of non-aqueous solvents is not desir
able.

longed period of time.
US. Pat. No. 5,780,045 by McQuinn et al. relates to a
transmucosal drug delivery device in the form of a sheet
35
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The adhesive layer is comprised of water-soluble cellulose
based polymers and polyacrylic acid while the nonadhesive
layer is comprised mostly of materials with no adhesive prop

comprising an acid-containing particulate polymer dispersed
in a polytetra?uoroethylene support matrix. The McQuinn
patent does not teach the use of ?lm-forming gels comprised
of pH-sensitive polymers and water-insoluble mucoadhesive
polymers that form ?lms due to changes in pH and/ or desol
vation of the polymers. Further, the McQuinn patent does not
teach the use of pH-sensitive wax-?lm composites intended
to remain adhered to the skin or mucosal surface for a pro

longed period of time.
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US. Pat. No. 4,552,751 by Inaba et al. relates to the prepa
ration of multi-layered ?lms of three, ?ve, or seven layers for
the administration of speci?c prostaglandins to mucosal sites.
The Inaba patent does not teach the use of ?lm-forming gels

comprised of pH-sensitive polymers and water-insoluble
50

mucoadhesive polymers that form ?lms due to changes in pH
and/or desolvation of the polymers. Further, the Inaba patent
does not teach the use of pH-sensitive wax-?lm composites
intended to remain adhered to the skin or mucosal surface for

Different types of formulations to deliver drugs topically
are known in the art. Speci?c examples are illustrated below.
US. Pat. No. 4,715,369 by Suzuki et al. relates to methods
to treat the injured oral mucosa with a thin two-layer tablet
comprised of both an adhesive layer and a nonadhesive layer.

vation of the polymers. Further, the Tapolsky patent does not
teach the use of pH-sensitive wax-?lm composites intended
to remain adhered to the skin or mucosal surface for a pro

these systems tend to be easily and quickly washed away from
the application site within minutes after application. This is
very undesirable if the drug must remain at the application
site for a prolonged period in order to be ef?cacious. In an

sky patent does not teach the use of ?lm-forming gels con

taining at least 25% water by weight and comprised of pH
sensitive polymers and water-insoluble mucoadhesive

described in the literature. These formulations are designed
either for adherence of the dosage form to the skin (for dermal
or transdermal delivery of drugs) or mucosal surface (for

mucosal or transmucosal delivery of drugs). For skin delivery,
formulations generally consist of dermal patches, pastes,
band-aids, gels, lotions, sprays, or creams. For mucosal deliv
ery, formulations generally consist of gels, creams, tablets,

face or skin, the non-aqueous solvent, primarily ethanol,
evaporates, diffuses, or penetrates the surrounding tissue,
resulting in precipitation of the non water-soluble polymers

a prolonged period of time.
US. Pat. No. 4,517,173 by Kizawa et al. relates to a ?lm
55

preparation consisting of at least three layers, including a
pharmaceutical layer, a poorly water-soluble layer, and an
intermediate layer. The pharmaceutical layer consists of pre
donisolone and allantoin together with a water-soluble cellu

lose-based polymer. The poorly water-soluble layer consists
60

of shellack or fatty acids. The Kizawa patent does not teach

erties. The Suzuki patent does not teach the use of ?lm

the use of ?lm-forming gels comprised of pH-sensitive poly

forming gels comprised of pH-sensitive polymers and water

mers and water-insoluble mucoadhesive polymers that form

insoluble mucoadhesive polymers that form ?lms due to

?lms due to changes in pH and/or desolvation of the poly

changes in pH and/or desolvation of the polymers. Further,

mers. Further, the Kizawa patent does not teach the use of

the Suzuki patent does not teach the use of pH-sensitive
wax-?lm composites intended to remain adhered to the skin
or mucosal surface for a prolonged period of time.
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pH-sensitive wax-?lm composites intended to remain
adhered to the skin or mucosal surface for a prolonged period
of time.
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The solvent vehicle may be comprised of at least 25 to 100
parts water or buffered water with 0 to 75 parts of ethanol,

Us. Pat. No. 5,192,802 by Rencher describes the use of a

bioadhesive teething gel comprising benzocaine, sodium car
boxy methyl cellulose; an agent selected from the group

propylene glycol, glycerin, polyethylene glycol, or combina

consisting of xanthan gum and sodium alginate and a diluent

tions thereof. The water-insoluble swellable mucoadhesive

selected from the group consisting of polyethylene glycol and
polyethylene glycol with glycerine. U.S. Pat. No. 5,314,915

polymer may be polyacrylic acid cross-linked with polyalk
enyl ether or divinyl glycol, wherein the water-insoluble

by Rencher and Us. Pat. No. 5,298,258 by Akemi et al. also
agents. These patents do not teach the use of ?lm-forming

swellable mucoadhesive polymer is preferably, NOVEON or
CARBOMER. The water-insoluble swellable mucoadhesive
polymer may be present at a concentration of from 0.1% to

gels comprised of pH-sensitive polymers and water-insoluble

20% by weight.

mucoadhesive polymers that form ?lms due to changes in pH
and/ or desolvation of the polymers. Further, these patents do

acid and acrylic or methacrylic ester. Preferably, it is present

describe the use of aqueous or oil-based bioadhesive gelling

The pH-sensitive polymer is a copolymer of methacrylic

not teach the use of pH-sensitive wax-?lm composites
intended to remain adhered to the skin or mucosal surface for

a prolonged period of time.
U.S. Pat. Nos. 5,081,157 and 5,081,158 by PomerantZ
relate to a ?lm-forming composition for topical application of

medicaments to body tissues. The ?lm-forming composition
includes hydroxypropyl cellulose, a volatile solvent, and an
esteri?cation agent which reacts with the hydroxypropyl cel
lulose to form a reaction product which is soluble in the
solvent. These patents do not teach the use of ?lm-forming

20

at a concentration of from 0.05% to 10% by weight. More
preferably, the polymer is a Eudragit polymer, or a chemical
derivative thereof.
The molecule of interest may comprise an active pharma
ceutical such as an antimicrobial, antiviral, antiin?ammatory,
antiseptic, antihistamine, a local anesthetic, a disinfectant, a
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a
sweetener, a ?avoring agent, a diagnostic agent, or combina
tion thereof. Preferably, the molecule of interest is amlex

anox, triclosan, peptide, protein, hirudin, plasmid DNA,

gels comprised of pH-sensitive polymers and water-insoluble

lidocaine, benzocaine, dyclonine, or benzodiazepine drug or

mucoadhesive polymers that form ?lms due to changes in pH
and/ or desolvation of the polymers. Further, these patents do

a derivative thereof.
25

The invention is also directed to a pharmaceutical gel

not teach the use of pH-sensitive wax-?lm composites

which when applied to the skin or mucosal surface forms a

intended to remain adhered to the skin or mucosal surface for

?lm, said gel comprising a solvent vehicle, at least one water
insoluble swellable mucoadhesive polymer, at least one pH
sensitive ?lm-forming polymer, and at least one molecule of
interest, wherein said ?lm is formed due to changes in pH and

a prolonged period of time.
U.S. Pat. No. 4,900,554 by Yanagibashi et al. relate to the
use of a device for the delivery of drugs in the oral cavity. The
device comprises an adhesive layer consisting of at least one
acrylic acid polymer, a water-insoluble cellulose derivative,

30

desolvation of the polymer, and wherein said ?lm provides
for the delivery of the molecule of interest to or through the
application site. The solvent vehicle may be comprised of at

and a pharmaceutical preparation, and a water-insoluble or

least 25 to 100 parts water with 0 to 75 parts of ethanol,

sparingly soluble backing layer. Yanagibashi et al. state that
“it is impossible to achieve an adhesive device for application

35

propylene glycol, glycerin, polyethylene glycol, or combina

to body tissue without all three components, that is, acrylic

tions thereof. The water-insoluble swellable mucoadhesive

acid polymer, water insoluble cellulose derivative and water

polymer may be polyacrylic acid cross-linked with polyalk
enyl ether or divinyl glycol. Preferably, the water-insoluble

insoluble or sparingly soluble backing layer”. The
Yanagibashi patent does not teach the use of ?lm-forming

gels comprised of pH-sensitive polymers and water-insoluble

swellable mucoadhesive polymer is NOVEON or CAR
40

BOMER. The water-insoluble swellable mucoadhesive poly

mucoadhesive polymers that form ?lms due to changes in pH
and/ or desolvation of the polymers. Further, the Yanagibashi

mer may be present at a concentration of from 0.1% to 20% by

patent does not teach the use of pH-sensitive wax-?lm com
posites intended to remain adhered to the skin or mucosal

The pH-sensitive polymer may be a copolymer of meth
acrylic acid and acrylic or methacrylic ester. Preferably, it is

surface for a prolonged period of time.
As illustrated, the references described above appear to
lack preferred compositions and properties for an ef?cacious

weight.
45

and pharmaceutically acceptable bioadhesive delivery sys
tem. Namely, the references do not describe primarily aque

ous-based ?lm-forming gels comprised of pH-sensitive poly

50

mers and water-insoluble mucoadhesive polymers that form

?lms due to changes in pH and/or desolvation of the poly
mers. Further, the references do not describe pH-sensitive
mucoadhesive wax-?lm composites intended to remain
adhered to the skin or mucosal surface for a prolonged period
of time.

anox, triclosan, peptide, protein, hirudin, plasmid DNA,
55

lidocaine, benzocaine, dyclonine, or benzodiazepine drug or

60

a derivative thereof. The application site may be the skin,
mouth, vagina, nose, nasal cavity, or other accessible mucosal
site.
The invention is also directed to a wax-?lm composite
comprised of a pH-sensitive mucoadhesive layer and a water

SUMMARY OF THE INVENTION

The invention is directed to a pharmaceutical gel compo

insoluble wax layer. The pH-sensitive mucoadhesive layer

sition comprising:

may be present at a concentration of 20% to 90% by weight,

a solvent vehicle,
at least one water-insoluble swellable mucoadhesive poly
mer,

at least one pH-sensitive ?lm-forming polymer, and
at least one molecule of interest.

present at a concentration of from 0.05% to 10% by weight.
More preferably, the polymer is a Eudragit polymer, or a
chemical derivative thereof.
The molecule of interest may comprise an active pharma
ceutical such as an antimicrobial, antiviral, antiin?ammatory,
antiseptic, antihistamine, a local anesthetic, a disinfectant, a
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a
sweetener, a ?avoring agent, a diagnostic agent, or combina
tion thereof. Preferably, the molecule of interest is amlex

and the water-insoluble wax layer may be present at a con
65

centration of 10% to 80% by weight. The pH-sensitive
mucoadhesive water-insoluble layer may be comprised of:
at least one water-insoluble swellable mucoadhesive poly
mer,

US 7,803,392 B2
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at least one pH-sensitive ?lm-forming polymer, and

The invention is also directed to a method of making the

above pharmaceutical gel composition, comprising:

at least one molecule of interest.

(i) adding a mucoadhesive polymer to a stirring water to
form a solution that is clear and viscous,

The water-insoluble swellable mucoadhesive polymer
may be polyacrylic acid cross-linked with polyalkenyl ether
or divinyl glycol. Preferably, the water-insoluble swellable

(ii) adding the pH-sensitive ?lm-forming polymer to the
solution formed in step (i) and measuring the pH of the

mucoadhesive polymer is NOVEON or CARBOMER. The

water-insoluble swellable mucoadhesive polymer may be
present at a concentration of from 0.1% to 20% by weight.
The pH-sensitive polymer may be a copolymer of meth
acrylic acid and acrylic or methacrylic ester. Preferably, it is
present at a concentration of from 0.05% to 10% by weight.
More preferably, the polymer is a Eudragit polymer, or a
chemical derivative thereof.
The molecule of interest may comprise an active pharma
ceutical such as an antimicrobial, antiviral, antiin?ammatory,
antiseptic, antihistamine, a local anesthetic, a disinfectant, a

solution,
(iii) adding the molecule of interest to the solution of step
10

The invention is also directed to a method of making the

above wax-?lm composite, comprising:
(i) forming a homogeneous mucoadhesive ?lm by fusing a
mucoadhesive polymer and a pH-sensitive ?lm-forming

polymer,
(ii) homogeneously coating one side of the mucoadhesive
?lm of step (i) with a melted wax composition, and
(iii) drying the wax composition to form the wax-?lm
composite, wherein the molecule of interest is added in
either step (i) or (ii), or the molecule of interest is added
to the mucoadhesive side after the wax-?lm composite is
formed.

keratolytic, an analgesic, an anti-migraine, an anti-fungal, a
sweetener, a ?avoring agent, a diagnostic agent, or combina

tion thereof. Preferably, the molecule of interest is amlex

anox, triclosan, hirudin, plasmid DNA, lidocaine, ben
zocaine, dyclonine, or benzodiazepine drug or a derivative
thereof. The wax-?lm composite may comprise at least one

water-insoluble pharmaceutical wax having a melting point

(ii), and
(iv) forming the ?nal gel composition.

Furthermore, the invention is also directed to a method of
treating a disease or an illness by administering to a person in
25

between 40° C. and 100° C. and at least one water-soluble or

need thereof, the gel or the wax-?lm composite as described
above comprising a molecule of interest.

water-swellable polymer.
BRIEF DESCRIPTION OF THE DRAWINGS

The wax may be DENTSPLY® Utility Wax (Dentsply

Prosthetics, York, Pa.), beeswax, emulsifying wax, microc
rystalline wax, carnauba wax, para?in wax, white wax, yel

30

low wax, or other suitable pharmaceutical wax. The water

soluble or swellable polymer may be present in the insoluble
wax layer at a concentration of 0.05 to 10% by weight. The

water-soluble or swellable polymer may be tragacanth, poly

vinyl pyrrolidone, polyvinyl alcohol, cross-linked poly

tion only, and thus are not limitative of the present invention,

and wherein;
35

acrylic acid, polyethylene glycol, a cellulose polymer deriva
tive, or other suitable pharmaceutical polymer that is water
soluble or water-swellable. In the wax-?lm composite, the
molecule of interest may be contained in and released from
either the pH-sensitive mucoadhesive layer or the water-in
soluble wax layer.
The molecule of interest comprises an active pharmaceu
tical compound such as an antimicrobial, antiviral, antiin
?ammatory, antiseptic, antihistamine, a local anesthetic, a

FIG. 1 shows a summary of the compositions of the inven
tion
FIG. 2 shows an in vitro adhesion time of 1A inch wax-?lm

composites (n:3 each) on glass submerged in 40 mM
KH2PO4/NaOH buffer, pH 6 at 37° C. (unstirred). Each
40

mucoadhesive layer contains 5.0i5.3 mg of total polymer
comprised of NOVEON and EUDRAGIT S100 in the ratios
indicated. The wax layer consists of DENTSPLY® Utility
Wax containing 1% w/w tragacanth polymer. *Indicates that
different volumes of mucoadhesive gels were cast as

45

disinfectant, a keratolytic, an analgesic, an anti-migraine, an

anti-fungal, a sweetener, a ?avoring agent, a diagnostic agent,
or a combination thereof. The molecule of interest may com

described in Example 8. See Table 1 and Example 8 for
additional details.
FIG. 3 shows in vitro adhesion time of 1A inch wax-?lm

composites (n:3 each) on glass submerged in 40 mM
KH2PO4/NaOH buffer, pH 6 at 37° C. (stirred at 100 rpms).

prise an active pharmaceutical such as an antimicrobial, anti

viral, antiin?ammatory, antiseptic, antihistamine, a local

The present invention will become more fully understood

from the detailed description given hereinbelow, and the
accompanying drawings which are given by way of illustra

50

Each mucoadhesive layer contains from 1.2 mg to 11.2 mg of

anesthetic, a disinfectant, a keratolytic, an analgesic, an anti
migraine, an anti-fungal, a sweetener, a ?avoring agent, a

total polymer comprised of NOVEON and EUDRAGIT S100

diagnostic agent, or combination thereof. Preferably, the mol

DENTSPLY® Utility Wax containing 1% w/w tragacanth

ecule of interest is amlexanox, triclosan, protein, peptide,
hirudin, plasmid DNA, lidocaine, benzocaine, dyclonine, or

in a weight ratio of 3:1. The wax layer consists of

polymer. See Table 2 and Example 9 for additional details.
55

benzodiazepine drug or a derivative thereof. Preferably, the
hirudin may be complexed with a substance of opposite

rated during the manufacturing process (‘preload’) or ali
quoted onto the mucoadhesive layer after the manufacturing

charge. More preferably, the substance of opposite charge
may be chitosan or protamine. Alternatively, the molecule of
interest may be a plasmid DNA or plasmid DNA complexed
with a substance of opposite charge such as chitosan, prota

FIG. 4 shows in vitro adhesion time of 1A inch wax-?lm

composites containing plasmid DNA (10 pg) either incorpo

60

process (‘postload’). Wax-?lm composites (n:5 each) were
adhered to glass and submerged in 40 mM KHZPO4/NaOH
buffer, pH 6 at 37° C. (unstirred). See Example 10 for addi

mine, or a cationic lipid.

tional details.

The application site for the wax-?lm composite may be the
skin, mouth, vagina, nasal cavity, or other accessible mucosal
site. Preferably, the wax-?lm composite adheres to the appli

as measured by the PicoGreen DNA Quantitation Kit (from

cation site for at least 1 hour. Preferably, the wax-?lm com
posite has a total thickness of less than 5 mm.

FIG. 5 shows a standard curve forplasmid DNA in solution
65

Molecular Probes, Inc., Eugene, Oreg.).
FIG. 6 shows the release of plasmid DNA pre-loaded into
wax-?lm composites. Wax-?lm composites were made as

US 7,803,392 B2
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described in Example 10 using a mucoadhesive gel com

The pH-sensitive mucoadhesive ?lm-forming gel is a phar

prised of NOVEON/EUDRAGIT S100 (3:1 w/w) and plas

maceutical gel which when applied to the skin or mucosal
surface forms a ?lm, said gel comprising a solvent vehicle, at
least one water-insoluble swellable mucoadhesive polymer,
at least one pH-sensitive ?lm-forming polymer, and at least
one molecule of interest, said ?lm forming due to changes in

mid DNA. The wax layer consists of DENTSPLY® Utility

Wax containing 1% w/w tragacanth polymer. Five 1A inch
wax-?lm composites containing of plasmid DNA (5 pg) were
submerged separately into 1 mL 10 mM PBS buffer, pH 7.4 at
37° C. At various times, exactly 100 uL solution was ali

pH and desolvation of the polymer, said ?lm providing for the
delivery of the molecule of interest to or through the applica

quoted for DNA quantitation using the PicoGreen DNA

tion site.
The pH-sensitive mucoadhesive wax-?lm composite is a
bi-layer pharmaceutical ?lm less than 5 mm in diameter that
when applied to the skin or mucosal surface adheres to the
application for at least 1 hour. The wax-?lm composite is
comprised of a pH-sensitive mucoadhesive layer and a water
insoluble wax layer.

Quantitation Kit. Exactly 100 uL fresh PBS was added to
replace the removed volume at each time point.
FIG. 7 shows the release of plasmid DNA post-loaded into
wax-?lm composites. Wax-?lm composites were made as
described in Example 10 using a mucoadhesive gel com

prised of NOVEON/EUDRAGIT S100 (3:1 w/w). The wax
layer consists of DENTSPLY® Utility Wax containing 1%
w/w tragacanth polymer. Plasmid DNA (5 pg) was added to
?ve individual 1A inch wax-?lm composites, allowed to air
dry for 4 hours, and then submerged separately into 1 mL 10
mM PBS buffer, pH 7.4 at 370 C. At various times, exactly
100 uL solution was aliquoted for DNA quantitationusing the
PicoGreen DNA Quantitation Kit. Exactly 100 uL fresh PBS

De?nitions and Preferred Embodiments
As used herein, certain terms may have the following

de?ned meanings.
20

clearly dictates otherwise. For example, the term a pharma

was added to replace the removed volume at each time point.

ceutical may refer to one or more pharmaceuticals for use in

FIG. 8 shows: (A) The reaction kinetics of Chromozym

the presently disclosed formulations and methods.

TH and uncomplexed thrombin. Hirudin was added to excess

thrombin and residual uncomplexed thrombin was assayed

25

spectroscopically after the addition of Chromozym-TH.

tive elements, synthetic or natural small molecules, peptides,
proteins, nucleic acids, or any combinations thereof.
The term active pharmaceutical means any synthetic or
30

(thrombin in the presence of substrate only) and the hirudin

Nucleosil® 5 pm analytical column (4.6><250 mm). The
mobile phase consisted of water:acetonitrile:tri?uoroacetic
acid (59.95:40:0.05 w/w/w). The ?ow rate was 0.6 mL/min.
Each 50 uL sample of each standard curve was injected three

to be administered to a warm-blooded mammal to elicit a

pharmacological response. The terms pharmaceutical, active
35

FIG. 11 shows the Zeta Potential of Hirudin/Chitosan
Complexes in water made with Hirudin at a Concentration of
0.1 mg/mL. Zeta Potential values are reported as the mean
and standard deviation of three measurements.
FIG. 12 shows the stability of Hirudin/Chitosan Com
plexes (4:1 w/w) made in water as function of Hirudin con
centration and storage time. All samples were stored at 4° C.

40
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monoclonal antibody, polyclonal antibody, nucleic acid, or
combinations thereof. More preferably, the active pharma
ceutical is amlexanox, triclosan, lidocaine, dyclonine, ben
zocaine, a benzodiazepine, hirudin, antisense oligonucle

2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano-[2,3
50

Chitosan complexes in water was diluted in 900 uL ethanol to
55

DETAILED DESCRIPTION OF THE INVENTION

b]-pyridine-3-carboxylic acid. Amlexanox is the active ingre
dient in the commercial product, Aphthasol, which acceler
ates the healing of aphthous ulcers in the mouth by an
unknown mechanism (Binnie et al. 1997; Khandwala et al.
1997a; Khandwala et al. 1997b). The Aphthasol product is a
5% paste. In cell culture experiments, Amlexanox has been
shown to inhibit the formation or release of in?ammatory
mediators such as histamine and leukotrienes from mast cells,

The invention relates to delivery systems suitable for the

topical and mucosal delivery of molecules of interest. Spe
ci?cally, the invention relates to; 1) compositions of pH
sensitive mucoadhesive ?lm-forming gels, 2) uses of pH

in?ammatory, antiseptic, antihistamine, tranquilizer, seda
tive, anti-nausea, local anesthetic, disinfectant, keratolytic,
analgesics including anti-migraine, anti-fungal, sweetener,
?avoring agent, diagnostic agent, peptide, protein, antigen,

otide, or plasmid DNA, or any derivative or combinations
thereof.
Amlexanox: The chemical name of Amlexanox is

For the Day 7 sample analysis, exactly 100 uL of Hirudin/
determine the stability of the complexes in ethanol.

pharmaceutical, and drug as used herein are identical in

meaning and thus are used interchangeably. It is preferred that
the active pharmaceutical be an anti-microbial, antiviral, anti

times and the average AUC was plotted.
FIG. 10 shows the Particle Size of Hirudin/Chitosan Com
plexes in water made with hirudin at a Concentration of 0.5

mg/mL.

naturally occurring substance including elements, radioac
tive elements, synthetic or natural small molecules, peptides,
proteins, nucleic acids, or any combinations thereof intended

difference between the thrombin base value absorbance
sample values versus the concentration of hirudin standards
from A.
FIG. 9 shows an HPLC Standard Curve for Hirudin. Three
standard curves for hirudin were generated using a C18

The term molecule of interest is de?ned as any synthetic or

naturally occurring substance including elements, radioac

Hirudin was added to the 1.0 ml volume in the following

amounts: 0 ng (III), 16.9 ng (C), 33.8 ng (A), 50.7 ng (A), 67.6
ng (o), and 84.4 ng (I). (B) Calibration curve for released
hirudin in solution. The ?gure was made by plotting the

As used in the speci?cations and claims, the singular form
a, an and the include plural references unless the context

60

neutrophils, and mononuclear cells (Urisu et al. 1990). Eur
ther, in animals, Amlexanox has anti-allergic and anti-in?am
matory properties and has been shown to inhibit both imme
diate and delayed hypersensitivity reactions (Saijo et al.
1985; Saijo et al. 1986). Amlexanox has very poor solubility

sensitive mucoadhesive ?lm-forming gels, 3) compositions

in ethanol (0.58 mg/mL) and water (0.005 mg/mL). However,

of pH-sensitive mucoadhesive wax-?lm composites, and 4)

the solubility of Amlexanox increases with pH.

uses of pH-sensitive mucoadhesive wax-?lm composites. A
summary of the compositions of the invention is shown in
FIG. 1.
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Triclosan: The chemical name of Triclosan is 2,4,4'

Trichloro 2'-hydroxy-diphenyl-ether 5-chloro 2-(2,4-dichlo
rophenoxy)-phenol. Triclosan is a broad-spectrum antibacte

US 7,803,392 B2
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(e.g., activate central GABAergic neuroinhibition, thereby
inducing anxiolysis, sedation/hypnosis, anticonvulsion and

rial that has activity against a wide range of gram-positive and

gram-negative bacteria (Zuckerbraun et al. 1998). Triclosan
has been shown to inhibit bacterial fatty acid synthesis at the

muscle relaxation. In turn, benzodiazepines are used for the
treatment of seizures and insomnia, preoperative or proce
dural sedation, and for the treatment of nausea and anxiety.
Most if not all of the benzodiazepine bases have little or no
solubility in water and are very lipophilic (Hjortkjaer et al.
1999, Bechgaard et al. 1997). As a result, a great deal of

enoyl-acyl carrier protein reductase (Fabl) step (Heath et al.
1999). It has gained wide-spread use as antibacterial agent
that is used in toothpastes, kitchen utensils and toys. Triclosan
has also been formulated in mouthwashes (Mandel 1994) and
liposomes (Jones et al. 1993). Triclosan has a pKa of7.9 and
is insoluble in water, except in alkaline solutions where it is

research has gone into developing ef?cacious dosage forms

of these drugs including; i) synthesizing water-soluble

readily soluble (Loftsson et al. 1999). However, triclosan is
soluble in ethanol and polyethylene glycol 400 and many
other organic solvents.

derivatives such as their hydrochloride salts, ii) developing
injectable formulations of the benzodiazepine bases that do
not result in precipitation of the drugs, and iii) exploring

Hirudin: Hirudin is the most potent and speci?c known

inhibitor of thrombin (KZ:0.2 pM) (Markwardt 1989; Mark
wardt 1991a; Markwardt 1991b; Fenton et al. 1991). Hirudin
was originally isolated from medicinal leeches (Hirudo
medicinalis), but is now available in large quantities due to
recombinant techniques (Riehl-Bellon et al. 1989). Unlike
heparin, hirudin does not require endogenous cofactors to
function and does not have associated bleeding complica
tions. Hirudin is a relatively small 65 amino acidpeptide (Mw
7000) with remarkable stability over a broad range of pH (pH
3*10), temperature (i.e., up to 60° C.), and solvent conditions
(Chang 1991; Eric and Caroline 1991). The main structure of
hirudin is characterized by an apolar disul?de knot with a

alternative routes of administration including intranasal, rec
tal, and buccal. Previous work has shown that intranasal doses

of the benzodiazepine bases dissolved in organic solvents
lead to pharmacological responses with suitable pharmaco
kinetic pro?les. However, the repeated use of organic solvents

such as ethanol, polyethylene glycol, and propylene glycol
20

benzodiazepines have been given by buccal administration
with very favorable results (Schwagmeier et al. 1998; Scott et

al. 1999). For example, Schwagmeier et al. showed that the
25

very anionic (negatively-charged) tail. The apolar knot of
hirudin masks the catalytic site of thrombin by interacting

maximum plasma concentration of midazolam was 55.9
ng/mL at 30 minutes following buccal administration of 5 mg
midazolam with a mean bioavailability of 74.5%. Scott et al.

with its apolar site (i.e., via hydrophobic interaction). The
anionic tail of hirudin (18 amino acids) interacts with the
anion-binding exosite of thrombin. It is the combination of
the apolar binding and the anion-binding that accounts for the

for intranasal administration is not desirable. Alternatively,
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reported that the buccal administration of 10 mg midazolam
per 2 mL stopped 75% (30/40) seizures in children within an
average time of 6 minutes after administration. Thus, buccal
administration of benzodiazepines may be an attractive alter
native to injection or intranasal administration. It is envi

very high af?nity of hirudin and thrombin. The presence of

sioned that the said pH-sensitive mucoadhesive ?lm-forming

the apolar knot and anionic tail on hirudin results in both

known to interact with cell membranes while the anionic tail

gel or wax-?lm composite containing a benzodiazepine can
easily be applied to the buccal tissue in the mouth and provide
a means to safely and reproducibly deliver doses of the ben
zodiazepines for the treatment of seizures and insomnia, pre
operative or procedural sedation, and for the treatment of

remains extracellular (Fenton 1989). It is likely that the
anionic portion of hirudin is electrostatically repelled from

nausea and anxiety. Benzodiazepines suitable for delivery
are, but not limited to, alprazolam, camazepam, clobazam,

hydrophobic and hydrophilic surface interactions. For
example, in solution, hirudin forms micellar complexes (e.g.,
tetramers) with itself. Further, the apolar region of hirudin is

the surface of cell membranes. Novartis Pharma obtained

35
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marketing approval in the European Union in 1998 for
REVASC (desirudin; recombinant hirudin) for the prevention

zolam, nitrazepam, oxazepam, pinazepam, prazepam, triaz

of deep-vein thrombosis following knee and hip replacement
surgery. In clinical trials, patients receiving hirudin by sub
cutaneous injection twice a day for 8 days had a nearly 30%
lower overall rate of deep-vein thrombosis than those who
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received low molecular weight heparin (Eriksson et al 1997).
Novartis is also performing clinical trials (Phase III) for the
use hirudin in acute coronary syndrome. Several other indi
cations for hirudin are being pursued such as stasis-induced
venous thrombosis, diffuse microthrombosis, and hemodi
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of hirudin require blood levels between 80 to 3500 ng/mL

(Markwardt 1989, Markwardt 1991). A potential problem
55

effective antidotes for hirudin overdosing. If upon frequent
injection, the wrong dose is given, there are no methods to
turn the activity of hirudin off. For this reason alone, hirudin
is a good candidate for transmucosal delivery via the buccal
tissue. It is envisioned that the pH-sensitive mucoadhesive

olam, and derivatives and combinations thereof.
The term pharmaceutically acceptable means that the sub
stance is generally regarded to be safe when used in such a
manner that is widely acceptable by those skilled in the art.
For reference of acceptable materials, refer to THE UNITED
STATES PHARMACOEPIA.
The term pH-sensitive is de?ned as a substance that is

alysis (Markwardt 1989). Most of the potential applications
with the use of injected forms of hirudin is that there are no

clonazepam, desmethyldiazepam, diazepam, ?unitrazepam,
?urazepam, halazepam, lorazepam, lormethazepam, mida
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affected by changes in pH so that the substance changes
conformation, charge, solubility, or combinations thereof. A
pH-sensitive polymer is de?ned as polymer that is affected by
changes in pH so that the polymer changes conformation,
charge, solubility, or combinations thereof. A pH-sensitive
?lm-forming polymer is de?ned as polymer that is affected by
changes in pH so that the polymer changes conformation,
charge, solubility, or combinations thereof resulting in the
precipitation, desolvation, or settling of the polymer into a
?lm. For the purposes of this invention, it is preferred that the
pH-sensitive ?lm-forming polymers have some solubility in

?lm-forming gel or wax-?lm composite containing hirudin,

aqueous-based vehicles above pH 5 but limited or no solubil

can easily be applied to the buccal tissue in the mouth and
provide a means to safely control the dosing and dose sched

ity below pH 5. It is more preferred that the pH-sensitive
?lm-forming polymers have some solubility in aqueous

uling of hirudin.
Benzodiazepines: Benzodiazepines are among the most

frequently prescribed drugs in the Western world. All benzo
diazepine agonists exert similar pharmacodynamic actions

based vehicles above pH 6 but limited or no solubility below
65

pH 6. It is most preferred that the pH-sensitive ?lm-forming
polymers have some solubility in aqueous-based vehicles
above pH 7 but limited no solubility below pH 7. Examples of
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pH-sensitive ?lm-forming polymers that meet these criteria

wax, microcrystalline wax, camauba wax, paraffin wax,

are, but not limited to, Eudragits® and cellulose acetate

white wax, yellow wax, or other suitable pharmaceutical wax.
It is preferred that the wax has a melting temperature between
40° C. and 100° C., more preferred that the wax has a melting

phthalate polymers, or derivatives thereof.
Eudragits® are synthetic cationic and anionic polymers of
methacrylic acid and methacrylic acid esters in varying ratios.

temperature between 40° C. and 80° C., and most preferred

The polymers are generally regarded as safe and are included

that the wax has a melting temperature between 40° C. and
65° C.

in the FDA Inactive Ingredients Guide (for oral capsules and

tablets). The presence of positive charge (provided by the

A wax-?lm composite refers to a bi-layer ?lm comprised of

dimethylaminoethylmethacrylates), neutral charge (provided
by the methacrylic acid esters) and negative charge (provided
by the methacrylic acid) residues provides for interesting and

a pH-sensitive mucoadhesive layer and a water-insoluble wax

layer. A molecule of interest may be loaded in and released
from either the said pH-sensitive mucoadhesive layer or said
water-insoluble wax layer. It is preferred that the molecule of
interest is present in the wax-?lm composite at a concentra

useful solubility characteristics as a function of pH. In gen
eral, the cationic Eudragits are soluble at lower pHs while the

anionic Eudragits are soluble at higher pHs. Neutral
Eudragits usually lack aqueous solubility at any pH. For the
purposes of this invention, any Eudragit polymer or derivative
thereof is preferred. Even more preferred is any anionic
Eudragit or derivative thereof. Most preferred is Eudragit
L100-55, Eudragit L100, and Eudragit S100 or derivatives
thereof. Depending on the type of Eudragit polymer selected
and its solubility as function of pH, ?lms having different

tion of 0.001% to 20% by weight, more preferably at a con

centration of 0.001% to 10% by weight, and most preferably
at a concentration of 0.001% to 5% by weight. It is preferred
that the pH-sensitive mucoadhesive layer is present at a con
centration in the wax-?lm composite of 20% to 90% by
weight, more preferably at 30% to 80% by weight, and most
20

insoluble wax layer is present at a concentration in the wax

properties can be prepared. Eudragit gels have been reported
for the sustained-release of drugs via rectal administration
(Goto et al. 1991; Kawata et al. 1991; Kim et al. 1992a; Kim
et al. 1992b; Kim et al. 1992c; Umejima et al. 1993). Eudragit

preferably at 40% to 70% by weight. Preferably, the water
?lm composite of 10% to 80% by weight, more preferably at
20% to 70% by weight, and most preferably at 30% to 60% by
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has also beenused in buccal patches (Wong et al. 1999). Wong

weight. For bonding the two layers of the bi-layer wax-?lm
composite, it is preferred that the water-insoluble wax layer
contain at least one water-soluble or water-swellable agents

et al. described the use of Eudragit patches with the water

such as, but not limited to, tragacanth, polyvinyl pyrrolidone,

soluble cellulose-based polymers and swellable Carbopol

polyvinyl alcohol, cross-linked polyacrylic acid, polyethyl

polymers to deliver a model drug. However, for these studies
Wong et al. utilized Eudragit NE40D, a neutral poly(ethy

ene glycol, a cellulose-based polymer or derivative thereof, a
30

cross-linked polyacrylic acid polymer or derivative thereof,

lacrylate methylmethacrylate) polymer that is insoluble at all
pHs (non-pH-sensitive). Eudragit has also been used to ?lm

or other suitable pharmaceutical polymers that are water
soluble or water-swellable. Preferably, the water-soluble or

coat tablets for pH-dependent colon targeting after oral deliv
ery (Khan et al. 1999). Cationic Eudragit E, which is soluble
at low pH, has also been proposed for the pH-controlled drug
release from mini-tablets for the treatment of in?ammatory
bowel disease (Leopold and Eikeler, 1998). No references or

water-swellable agents are present in the wax layer at a con
35

the following; any skin surface, rectal, vaginal, nasal cavity,

other prior art could be found that describe the use of mucoad

hesive gels comprised of anionic polymers, that when applied
to the skin or mucosal surfaces, form ?lms due to effect of pH

centration of 0.05% to 10% by weight, more preferably at 1%
to 8% by weight, and most preferably at 1% to 5% by weight.
It is envisioned that the wax-?lm composite may be applied to
any readily accessible topical site including, but not limited to
any location in the mouth, or other accessible topical or

40

mucosal surfaces. A dry wax-?lm composite will readily

on the solubility of the anionic polymers.

adhere to the surfaces described when the surfaces are wet

Solubility refers to the extent to which a solute is dissolved
in a solvent. Solubility can be described in terms such as
described in REMINGTON’S PHARMACEUTICAL SCI

with saliva or other bodily ?uids. However, for application to

ENCES 18th edition, 1990, ranging from very soluble (less

dry skin, it is envisioned that the dry wax-?lm composite
45

than 1 part of solvent per 1 part of solute) to insoluble (more
than 10,000 parts of solvent for 1 part of solute). The term
water-insoluble refers to a substance or solute where more

than 10,000 parts of water are needed to dissolve 1 part of
solute. A water-insoluble swellable substance refers to a sub

50

stance or solute that is water-insoluble but absorbs water and

swells to form a colloidal dispersion. A colloidal dispersion,
as de?ned by REMINGTON’S “consists of at least two dis

crete phases”, namely a solid phase and a liquid phase. The
term desolvation refers to phenomena whereby a solvent such
as water diffuses from a swelled substance leaving primarily
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one solid phase comprised of the substance. A gel is de?ned
as a semisolid consisting of particles interpenetrated by a
liquid. A gel solution is de?ned as a gel which has a molecule

of interest dissolved in solution in the liquid phase. A gel

could be easily wetted using tap water or another appropriate
vehicle to promote subsequent adherence of the ?lm to the
skin. It is preferred that the wax-?lm composite remain
adhered to the application site for at least 1 hour, more pref
erably for at least 75 minutes, and most preferably for at least
90 minutes.
The term mucoadhesive refers to a substance that sticks to
or adheres to the skin or mucosal surfaces by forces that are

measurable and by any number of mechanisms such as, but
not limited to the following: hydrogen-bonding, ionic inter
action, hydrophobic interaction, van der Waals interaction, or
combinations thereof.
Mucosal delivery is de?ned as the application of a formu
lation or delivery system containing one or more active phar
maceuticals to a mucosal site for the purpose of eliciting a

pharmacological response at the site of application or alter

suspension is de?ned as a gel which has a molecule of interest

natively, for the active pharmaceutical to be absorbed through
the mucosal membrane into the systemic circulation.

suspended in the liquid phase.

Mucosal sites applicable to the application of a formulation or
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tures of above 40° C. Suitable waxes are, but not limited to the

delivery system are, but not limited to the following, vaginal,
mouth, rectal, intranasal, and the eye.
Transmucosal Delivery: Peptides, proteins, and other
larger molecules are becoming increasingly more important

following, DENTSPLY® Utility Wax, beeswax, emulsifying

as scientists search for new drugs to treat serious human

A wax refers to any water-insoluble substance composed

of hydrocarbons, alcohols, fatty acids, and esters that are
solids at temperatures below 40° C., but liquids at tempera
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diseases. Most often, these new larger molecules have to be

A complex refers to the physical interaction between two
substances whereby a de?nite stoichiometry exists. Com
plexation can occur by any number of mechanisms, includ
ing, but not limited to: hydrogen-bonding, ionic interaction,

injected since bioavailability by other routes is low. However,

developing injectable large molecule drugs is expensive and
patient compliance is often low. Researchers in the ?eld of
drug delivery have sought for decades for methods to dose

hydrophobic interaction, van der Waals interaction, or com
binations thereof. It is envisioned that molecules of interest

larger molecules like peptides and proteins orally. However

formulated in said delivery systems may be complexed with
various pharmaceutically acceptable agents to enhance their
ef?cacy by any number of mechanisms described above, or

these drugs are prone to rapid and extensive degradation due
to the low pH of the stomach as well as to peptidases and

proteolytic enzymes throughout the gastrointestinal tract.

those still unknown.
Chitosan: Chitosan is a biodegradable polysaccharide

Alternative routes have been sought such as transmucosal

delivery via the lung, nose, and buccal tissue. The foreseen
advantages of transmucosal delivery are; i) a faster onset of

composed of two subunits, D-glucosamine and N-acetyl-D

activity (i.e., achieve higher drug blood levels faster), ii) the

glucosamine linked together by [3(1,4) glycosidic bonds.

avoidance of the ?rst hepatic pass metabolism and the related
increase of bioavailability, and iii) the avoidance of side
effects related to GI absorption (Rathbone et al. 1996). How
ever, the barriers for effective transmucosal delivery (i.e.,
buccal delivery) are similar to those for oral delivery. For
example, the oral mucosal tissue is also characterized by a
mucous layer that lines the epithelia. The mucous layer pro

When dissolved in solution, the amino groups present in the

glucosamine subunits (pKa 6.5) have a positive charge (Hen
riksen et al. 1997; Schipper et al. 1996). Chitosan is known to
be a mucoadhesive, and interacts ionically with the negatively
charged sialic acid residues in mucin (Lehr et al. 1992).
20

and drug carrier systems (Berthold et al. 1993; Shiraishi et al.
1993). Chitosan has also been found to increase the nasal
absorption of insulin and calcitonin (Illum et al. 1994;Aspden
et al. 1996), although the mechanism by which this occurs is

vides a substantial physical barrier as well as a chemical

barrier due to the presence of a multitude of peptidases and

proteolytic enzymes. In theory, delivery systems designed to
adhere to this mucous layer (i.e., mucoadhesives) can serve to

protect peptides from rapid and/or extensive degradation

25

(Takayama et al. 1990), and pectin and acacia (Meshali et al.
1993). One problem that may be encountered with the use of
30

stance of mucous. The viscosity of the mucous layer is largely

determined by the type and amount of the glycoproteins
present. Usually, the mucous layer in the oral mucosa is about
50(k600 pm thick and has a pH of 5.8i7.1. The combination
of the mucous layer and the epithelial layer provides a sub
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stantial barrier for signi?cant drug absorption. This is espe
cially true for peptide drugs that are prone to a high degree of
proteolytic degradation in the mucous layer. Further, if the

peptide drugs are anionic, the negatively-charged epithelial
membrane below the mucous provides a repulsive electrical
“fence” of sorts.
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chitosan (100 kDa) is the poor solubility of 100 kDa chitosan
at neutral pH. This lack of solubility may hinder its ability to
form complexes with hirudin or our ability to study the com
plex. A solution to this problem may be to obtain lower
molecular weight chitosans (i.e., 10 kDa or 50 kDa). How
ever, lower molecular weight chitosans are not commercially
available. In our previous work with chitosan (MacLaughlin
et al. 1998), we obtained lower molecular weight chitosans

using a modi?ed depolymerization technique ?rst described
by Peniston et al. (1975). This depolymerization process is a
relatively simple deamination reaction where chitosan is
chemically treated with sodium nitrite in 6% acetic acid at 25°
C. for 1 hour. The amount of sodium nitrite used in the

In general, the oral transmucosal bioavailability of pep
tides is low (<5%), but can be increased with the use of

penetration enhancers designed to disrupt the mucosal and
epithelial membranes (Sayani et al. 1993; Bhatt and Johnston,
1996; Bayley et al. 1995; Bhatt and Johnston, 1997). The

not clear. Finally, chitosan has been reported to form com

plexes with many negatively-charged molecules including
indomethacin (Imai et al. 1991), sodium hyaluronate

(Bodde et al. 1990; Duchene et al. 1988; Harris and Robinson
1990). The mechanism of mucoadhesion is complicated but is
known to involve hydrogen bonding between the components

of the delivery systems (i.e., polymers) and sialic acid resi
dues of mucin (0.5i2.0% glycoprotein), the primary sub

Chitosan has been used as a component of mucoadhesive
systems (Takeuchi et al. 1996), as well as a controlled release
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reaction determines the resulting chitosan molecular weight
since the reaction is stoichiometric. For example, reacting 1 g
of 100 kDa chitosan (Seacure 143) with 2% and 7% sodium
nitrite results in ?nal chitosan molecular weights of 50 kDa

most often used types of penetration enhancers are surfac

and 10 kDa, respectively. The depolymerized chitosan poly

tants (i.e., sodium lauryl sulfate), bile salts (i.e., sodium

mers are puri?ed and ready to use. The molecular weight of

deoxycholate), and fatty acids (i.e., oleic acid). Although
these penetration enhancers typically increase the absorption
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each depolymerized chitosan polymer is determined by gel
chromatography through a Beckman Ultraspherogel

of peptides, the safety and long term use of these agents is of

SEC2000 column with a 1 mL/min ?ow-rate of eluent 0.1M

concern. Further, these penetration enhancers, by design, do
not function to speci?cally protect peptides from proteolytic

acetic acid/sodium acetate buffer containing 0.05M sodium
chloride as the mobile phase.
Mucosal Vaccines: It is thought that the most effective

degradation in the mucosal membrane. Alternatively, a plau
sible strategy is to use more pharmaceutically acceptable
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excipients to physically protect peptides from rapid and
extensive proteolytic degradation, rather than to rely on
chemical means to disrupt biological membranes. For
example, to enhance the transmuccosal delivery of nega

tively-charged peptides, the peptides may be complexed with
pharmaceutically acceptable excipients that have positive

marketed vaccines except one (oral polio vaccine) are now
administered by inj ectable routes and are ineffective at induc
60

charges such as, but not limited to, chitosan, polylysine, or
protamine. It is thought that complexation will serve two

functions; i) decrease electrostatic repulsion of the peptide
drugs with the negatively-charged epithelial membrane, and
ii) decrease the extent of degradation of the peptide drugs by
proteolytic enzymes in the mucosal membrane.

vaccines for important viral and bacterial pathogens will
require mucosal immunity since this is the site at which these
pathogens infect the body (McGhee et al. 1992). However, all

ing mucosal immunity. A new promising ?u vaccine (Flu
mistTM from Aviron) is currently being tested in phase III
clinical trials. FlumistTM is administered as a nasal spray.

Since the nasal associated lymphoid tissue (NALT) is part of
the mucosal network, this vaccine is the ?rst of potentially
65

many new mucosal vaccines. Other mucosal routes are

actively being pursued by researchers including the vaginal
route and the mucosal regions of the gut (i.e., Peyer’s

